Navigation Links
NxStage(R) Reports Significant Interim FREEDOM Study Results

LAWRENCE, Mass., Oct. 27 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced the latest interim results from its ongoing FREEDOM study. The FREEDOM data will be presented in posters at the American Society of Nephrology (ASN) Renal Week 2009, from October 27th to November 1st in San Diego.

The FREEDOM analysis shows a significant reduction in the need for anti-hypertensive medications experienced by patients performing daily home hemodialysis (DHD) therapy with the NxStage System One(TM), and this reduction was maintained through the twelve month study period. These interim results from the FREEDOM study compared the number of anti-hypertensive medications (used to control blood pressure) that were prescribed at the patients' baseline (when they were on thrice-weekly, in-center hemodialysis), then at 4-months and 12-months after starting DHD. The study also looked at the number of patients who were not prescribed anti-hypertensive medications at those intervals. Key findings include:

  • A nearly 50% reduction in the average number of prescribed anti-hypertensive medications over 12 months;
  • 33% of patients completely discontinued anti-hypertensive medications; and,
  • 56% of patients experienced a 50% or greater decrease in anti-hypertensive medications.

Additional FREEDOM data demonstrates a 40% reduction in expected mortality of patients using daily home hemodialysis (DHD) therapy with the NxStage System One when compared to patients from the United States Renal Data System (USRDS). The Standardized Mortality Ratio (SMR), calculated from actual vs. expected deaths, was 0.6 for DHD patients compared to patients from the USRDS of similar age, gender, race and primary cause of ESRD.

"In an attempt to see if the decreased morality observed in the study would remain after statistical adjustment, this analysis utilized a well-established formula with conservative assumptions to calculate a SMR. Even after correcting for these variables, patients using daily home hemodialysis therapy with the System One experienced a significantly lower rate of death when compared to similar patients from the USRDS database," stated Brent Miller, M.D., an Investigator involved with the study from Washington University in St Louis. "This is further clinical evidence that more frequent home hemodialysis can lead to better clinical outcomes. These results should help energize patients, nephrologists, healthcare providers and public policy makers to continue to invest in and advance this therapy to alleviate the burden of dialysis."

Full abstracts can be read online at

About the FREEDOM Study

The FREEDOM study (Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements) is a multicenter prospective cohort study designed to measure the clinical and economic benefits of daily home hemodialysis, as compared to conventional, thrice-weekly in-center hemodialysis. The study will include up to 500 daily home hemodialysis patients at up to 70 clinical sites, and a matched cohort control group of 5,000 patients on conventional treatment chosen at random and derived from the USRDS database. All daily home hemodialysis patients use the NxStage System One(TM) as their treatment delivery system, and all have Medicare as their primary insurance payer. As part of the study, participants are asked to complete a series of Quality of Life surveys at the time of enrollment (baseline), at 4 and 12 months, and every 6 months thereafter as long as they remain in the study. NxStage Medical, Inc. is sponsoring the FREEDOM study.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of End Stage Renal Disease (ESRD) and acute kidney failure. For more information on NxStage and its products, please visit the company's website at

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to: expected growth in home daily hemodialysis and the anticipated impact and results of the FREEDOM study and other factors that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2009. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

    Kristen K. Sheppard, Esq.
    VP, Investor Relations

SOURCE NxStage Medical, Inc.

SOURCE NxStage Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. NxStage(R) to Report Third Quarter 2009 Financial Results
2. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
3. NxStage(R) to Recognize Several Key Milestones at American Society of Nephrologys Renal Week 2007
4. Hospira Reports Third-Quarter 2009 Results
5. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
6. Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance
7. Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders
8. Amylin Pharmaceuticals Reports Third Quarter Financial Results
9. Escalon(R) Reports Fourth Quarter and Fiscal 2009 Results
10. CareFusion Earns Top Ranking in MD Buyline and KLAS Reports
11. Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Post Your Comments:
(Date:6/26/2016)... , June 26, 2016 ... care operating models within the health care industry is ... financial efficiency , Deloitte offers a suite of ... business issues impacting efficient cost optimization: labor resource analysis, ... These services facilitate better outcomes and better economics ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
Breaking Medicine News(10 mins):